Mark Dybul yesterday took charge as executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, promising to accelerate the organization’s efforts to defeat these three highly infectious diseases by working closely with partners.
Dr Dybul, formerly a co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law at Georgetown University and named to the new post last fall (The Pharma Letter November 16, 2012), may be best known for playing a key role in creating, and later leading, PEPFAR - the largest global health initiative ever undertaken to address a single disease, which is widely credited with helping reverse the trend of AIDS, reducing new infection in many countries.
Dr Dybul outlined an ambitious and energetic agenda for the coming year. The Global Fund will launch a new funding model in February, allowing it to invest more strategically, engage implementers and partners more effectively and achieve greater impact in a way that improves the health and the lives of women and men and children all over the world.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze